目的 考察鹽酸安羅替尼膠囊聯(lián)合AP方案（注射用培美曲塞二鈉和順鉑注射液）治療晚期非小細胞肺癌的臨床療效。方法 選取2018年8月—2019年8月在漯河市郾城區(qū)人民醫(yī)院治療的80例晚期非小細胞肺癌患者，將所有患者隨機分為對照組和治療組，每組各40例。對照組患者采用AP方案，第1天靜脈滴注注射用培美曲塞二鈉，推薦劑量為500 mg/m²，溶于100 mL生理鹽水中，滴注時間為30 min，在靜注結(jié)束之后30 min靜脈滴注順鉑注射液，推薦劑量為75 mg/m²，溶于500 mL生理鹽水中，滴注時間為200 min。治療組患者在對照組基礎(chǔ)上口服鹽酸安羅替尼膠囊，1粒/次，1次/d。21 d為1個治療周期，兩組接受治療2個治療周期。觀察兩組患者臨床療效，比較兩組的無病生存期（PFS）、總生存期（OS）、卡氏功能量表（KPS）評分、肺癌生存質(zhì)量評價量表（FACT-L）評分、血清腫瘤標志物水平。結(jié)果 治療后，對照組客觀緩解率（ORR）和疾病控制率（CBR）分別為50.00%、62.50%；治療組ORR和CBR分別為65.00%、80.00%；治療組顯著較高（P<0.05）。治療后，治療組患者PFS和OS明顯高于對照組（P<0.05）。治療后，兩組KPS評分和FACT-L評分顯著升高（P<0.05），且治療組KPS評分和FACT-L評分明顯高于對照組（P<0.05）。治療后，兩組血清癌胚抗原（CEA）、糖類抗原125（CA125）、糖類抗原199（CA199）水平均顯著降低（P<0.05）；且治療組血清CEA、CA125、CA199水平明顯低于對照組（P<0.05）。結(jié)論 鹽酸安羅替尼膠囊聯(lián)合AP方案治療晚期非小細胞肺癌具有較好的治療效果，能夠提高患者生活質(zhì)量，降低血清腫瘤標志物水平。

Objective To investigate the efficacy of Anlotinib Hydrochloride Capsules combined with AP chemotherapy regimen (Pemetrexed Disodium for injection combined with Cisplatin Injection) in treatment of advanced non-small cell lung cancer. Methods Patients (40 cases) with advanced non-small cell lung cancer in Luohe Yancheng District People's Hospital from August 2018 to August 2019 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were treated with AP chemotherapy regimen, and iv administered with Pemetrexed Disodium for injection at first day, the recommended dosage 500 mg/m² added into normal saline 100 mL, and the infusion time was 30 min. After the end of intravenous injection for 30 min, the recommended dosage was 75 mg/m² added into normal saline 500 mL, and the infusion time was 200 min. Patients in the treatment group were po administered with Anlotinib Hydrochloride Capsules on the basis of the control group, 1 grain/time, once daily. A treatment cycle had 21 d, and patients in two groups were treated for 2 treatment cycles. After treatment, the clinical efficacies were evaluated, and PFS, OS, KPS score, FACT-L score, and serum tumor markers in two groups were compared. Results After treatment, the ORR and the CBR of the control group were 50.00% and 62.50%, respectively, and the ORR and the CBR of the treatment group were 65.00% and 80.00%, respectively, and the indexes of the treatment group was significantly higher than those of the control group (P<0.05). After treatment, the PFS and the OS of the treatment group were significantly higher than those of the control group (P<0.05). After treatment, KPS score and FACT-L score of two groups were significantly increased (P<0.05), and KPS score and FACT-L score of the treatment group were significantly higher than those of the control group (P<0.05). After treatment, the serum levels of CEA, CA125, and CA199 in two groups were significantly decreased (P<0.05), and the serum levels of CEA, CA125, and CA199 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Anlotinib Hydrochloride Capsules combined with AP chemotherapy regimen has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life of patients, and reduce the serum level of tumor markers.

R974